We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 8/1/2021

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

Journal Scan / Research · June 08, 2021

Androgen Deprivation Therapy With or Without Docetaxel in High-Risk Biochemically Recurrent Prostate Cancer After Surgery

European Urology Oncology

 

TAKE-HOME MESSAGE

abstract

This abstract is available on the publisher's site.

Access this abstract now   Full Text Available for ClinicalKey Subscribers

Additional Info

European Urology Oncology
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy With or Without Docetaxel in High-Risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)
Eur Urol Oncol 2021 May 18;[EPub Ahead of Print], MJ Morris, JM Mota, K Lacuna, P Hilden, M Gleave, MA Carducci, F Saad, ED Cohn, J Filipenko, G Heller, N Shore, AJ Armstrong, HI Scher

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.


Further Reading